Author

L. Farre

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:differential expression· 2 Approach:experimental assay· 2 Organism:human· 2 Approach:statistical model· 2 Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell type annotation· 1 Assay:ChIP-seq· 1

Frequent Co-Authors

A. Villanueva· 2 shared A. Andrade· 1 shared A. Bittencourt· 1 shared A. Gomez· 1 shared A. Jurgens· 1 shared A. Martinez-Marti· 1 shared A. Oaknin· 1 shared A. Vidal· 1 shared

Activity by Year

2018-2020 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 21 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

A. Villanueva

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

SMARCA4 deficient tumours are vulnerable to KDM6A/UTX and KDM6B/JMJD3 blockade

O. A. Romero, A. Villarrubi, J. J. Alburquerque-Bejar, A. Gomez, A. Andrade, D. Trastulli, E. Pros, S. Verdura, L. Farre, J. F. Martin-Tejera, P. Llabata, A. Oaknin, M. Saigi, J. M. Piulats, X. Matias-Guiu, , M. Sanchez-Cespedes

This study identifies KDM6A/UTX and KDM6B/JMJD3 as therapeutic targets in SMARCA4-deficient cancers, showing that their inhibition reduces tumor viability in mouse models.

bioRxiv · Aug 7, 2020Cancer Biology

Multiple Low Dose therapy: an effective strategy to treat EGFR inhibitor-resistant NSCLC tumours

J. M. Fernandes Neto, E. Nadal, S. N. Ooft, E. Bosdriesz, L. Farre, C. McLean, S. Klarenbeek, A. Jurgens, H. Hagen, L. Wang, E. Felip, A. Martinez-Marti, E. Voest, L. Wessels, O. van Tellingen, , R. Bernards

This paper shows that using multiple low doses of drugs targeting different components of a signaling pathway can effectively treat EGFR inhibitor-resistant NSCLC without resistance development.

bioRxiv · Oct 29, 2019Cancer Biology

Decreased RORC expression and downstream signaling in HTLV-1-associated Adult T-cell Lymphoma/Leukemia uncovers an antiproliferative IL17 link: a potential target for immunotherapy?

K. Subramanian, T. Dierckx, R. Khouri, S. M. Menzes, L. Farre, A. Bittencourt, K. Kataoka, S. Ogawa, J. Van Weyenbergh

The paper identifies decreased RORC expression and downstream antiproliferative IL17 signaling in ATL, suggesting therapeutic potential for boosting RORC/IL17 signaling.

bioRxiv · May 21, 2018Immunology